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Introduction: There exists over the past decades a constant debate driven by 
controversies in the validity of psychiatric diagnosis. This debate is grounded in queries 
about both the validity and evidence strength of clinical measures.
Materials and Methods: The objective of the study is to construct a bottom-up 
unsupervised machine learning approach, where the brain signatures identified by three 
principal components based on activations yielded from the three kinds of diagnostically 
relevant stimuli are used in order to produce cross-validation markers which may effectively 
predict the variance on the level of clinical populations and eventually delineate diagnostic 
and classification groups. The stimuli represent items from a paranoid-depressive self-
evaluation scale, administered simultaneously with functional magnetic resonance 
imaging (fMRI).
Results: We have been able to separate the two investigated clinical entities – 
schizophrenia and recurrent depression by use of multivariate linear model and principal 
component analysis. Following the individual and group MLM, we identified the three brain 
patterns that summarized all the individual variabilities of the individual brain patterns.
Discussion: This is a confirmation of the possibility to achieve bottom-up classification of 
mental disorders, by use of the brain signatures relevant to clinical evaluation tests.
Keywords: validation, psychopathology, machine learning, functional MRI, classification
INTRODUCTION
There exists over the past decades a constant debate driven by controversies in the validity of 
psychiatric diagnosis (1). This debate is grounded in queries about both the validity and evidence 
strength of clinical measures and the relevant classification and nomenclature systems (2) and 
eventually lead into crisis of confidence in psychiatry as medical discipline.
Those queries refer to a large extent to missing cross-validation of the clinical evaluation 
tools with data and explanatory models from neuroscience (3) and might be summarized in the 
following caveats.
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• Normative and validation standards in psychopathology are 
fragmented from basic neuroscience, which applies different 
validation standards and procedures, both on statistical and 
conceptual levels.
• Fundamentally psychiatric clinical measures are constituted 
from narratives of the patient (self-assessment scales), the 
informant, and the expert (clinical rating scales), which are 
essentially comprised of subjective introspective and inter-
subjective Likert scale items (4).
• Diagnostic entities in clinical psychiatry are not defined 
by biological signatures of disease as in the other medical 
disciplines, but with combinations and/or comparisons of 
those evaluation scales.
In our previous studies we have attempted to demonstrate 
the convergent and discriminative construct validity of the 
Depression Scale (5) and the functional magnetic resonance 
imaging (fMRI) signal by simultaneous administration of the 
items from the clinical scale as stimuli (6, 7). In those studies, 
we have employed neutral items from interest scale as contrast 
stimuli under block paradigm design. The t-contrasts on the 
second level of between-group comparison between patients 
with depression and healthy controls demonstrated significant 
differences in the activation of various brain regions during 
diagnostically significant scale items processing, contrasted with 
the processing of diagnostically neutral ones, notably in the left 
middle frontal gyrus, among others.
This paradigm has been further expanded by inclusion of 
paranoid items from Paranoid Depressive Scale (PD-S) by Von 
Zerssen and schizophrenia patients in order to investigate the 
contrast across different nosological groups and respective 
clinical measures (8). This model has been defined in top-down 
manner, from the clinical definition (psychiatric interview) 
to the corresponding brain activation determined by fMRI, 
administered simultaneously with clinical assessment scale 
(PD-S). Although certain encouraging results appeared on 
within-group level, they did not cross the statistical significance 
threshold on the between-group analysis level. We assumed 
that several factors undermine the translation of the functional 
MRI results to clinical measures in our data set. On one hand 
these disease entities might be assumed as a continuum of 
manifestation of one and the same underlying neurodegenerative 
or neuro-progressive process, as it is supported with reported 
abnormalities in the grey matter volume in patients with 
depression detected with voxel based morphometry (9–12). 
On the other hand, the included diagnoses may well represent 
discrete entities and the small number of recruited patients 
might be considered as confound in this study. Other caveats 
concern the innovative and non-conventional approach to 
the experimental paradigm design, which presents an issue 
for comparison with other studies in the field and the gender 
structure of the sample (8).
One critical premise of that model for translational validation 
is an exemplar instrumentalist validation (3), however including 
more robust biological reference measures. This approach is based 
on the assumption that scientific knowledge is instrumental: 
basically, it can provide us with suitable information about 
some limited domain of phenomena, and it explains and solves 
problems associated with that domain. In our case it would 
be instrumental to discriminate two clinical measurement 
constructs (paranoia and depression) with an incremental 
external validity operation, such as fMRI without any claim that 
those can delineate diagnostic entities in the medical sense, i.e. 
real nosological entities.
However, the data collected in our study are multi-
dimensional both in space with a large number of voxels 
and including multiple observations per variable and highly 
correlated. Therefore, we have decided to complement the more 
conventional two sample t-tests analysis with multivariate 
methods, namely multivariate linear model (MLM) (13). 
Multivariate analysis is widely used in studies with highly-
dimensional data and multiple variance. Furthermore, the 
method measures the strength of the relationship amongst 
variables and summarizes data about the individual differences. 
These methods have already been successfully applied to 
datasets from neuroimaging (14, 15) and on rather limited scale 
in psychiatry (16, 17).
AIM
In this context the aim of the present study is to identify by means 
of multivariate analysis the underlying biological signatures 
comprised of brain signals which may explain the variance 
across clinical diagnostic measures, presented simultaneously 
with the acquisition of the fMRI signal, such as depression (DS) 
and paranoid (PS) scale scores, particularly incorporated within 
PD-S, and diagnostically neutral (DN) items from the same 
interest scale as employed in our previous studies. In this way 
we may foster the diagnostic validity of the clinical measures and 
disease entities in question.
The objective of the study is to construct a bottom-up 
unsupervised machine learning approach, where the brain 
signatures identified by three principal components based 
on activations yielded from the three kinds of stimuli (DS, 
PS, and DN) are used in order to produce cross-validation 
markers which may effectively predict the variance on the level 




We recruited 30 adult psychiatric patients with either a diagnosis 
of schizophrenia (n = 16, mean age 36.4 ± 12.5 y, 10 males), or 
depressive episode (n = 14, mean age 45.3 ± 12.5 y, five males). 
Subjects were assessed by an experienced psychiatrist using 
a comprehensive clinical interview and the structured Mini 
International Neuropsychiatric Interview (M.I.N.I 6.0) (18) 
as well as the Montgomery-Åsberg Depression Rating Scale 
(MADRS) (19) and the Positive and Negative Syndrome Scale 
(PANSS) (20). Diagnosis was based on the clinical interview, 
the assessment scales, and the available information from past 
psychiatric examinations, as well as from relatives/caregivers.
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Inclusion criteria for the schizophrenic group were the 
following: 1) Diagnosis of Schizophrenia according to DSM-IV 
TR 2) Age 18 to 65 years. 3) PANSS total score at least 60. For 
the depression group subjects had to comply with the DSM-IV 
TR criteria for depressive episode (either in the context of major 
depressive or bipolar disorder), with MADRS score at least 20 
and age between 18 and 65 years.
Patients were excluded if they had a comorbid psychiatric 
disorder (such as anxiety, substance related disorder), major 
medical illness, neurological disease, history of head trauma with 
loss of consciousness, or metal implants not compatible with 
the MRI. All participants provided a written informed consent 
complying with the Declaration of Helsinki and the study was 
approved by the university’s ethics committee.
Data Acquisition
Patients were scanned on a 3Т MRI system (GE Discovery 750w), 
starting with a high resolution structural scan (Sag 3D T1 FSPGR 
sequence), slice thickness 1 mm, matrix 256х256, relaxation time 
(TR) 7.2 ms, echo time (TE) 2.3, and flip angle 12о, followed by 
a functional scan (2D EPI sequence), with slice thickness 3 mm, 
matrix 64 × 64, TR 2,000 ms, TE 30 ms, and flip angle 90о.
Paradigm
The paradigm consisted of three different active conditions and 
one rest condition, with a total duration of 11 min and 44 s 
presented in a classic block design. Each active block lasted for 
32 s and contained four text statements of 8 s. The statements 
of the Depression Specific (DS) and the Paranoia Specific (PS) 
blocks were taken from the von Zerssen depression and paranoia 
subscales accordingly. As in our previous study (7), there were also 
Diagnostically Neutral (DN) blocks consisting of four statements 
from a questionnaire about general interests and likes. Under 
each written statement four possible answers (“completely true,” 
“mostly true,” “somewhat true,” “not true”) and the respective four 
response buttons (upper left, lower left, lower right, upper right) 
were presented. In total there were four blocks of each type, and 
they were alternating between the three active conditions. After 
each active block a 20 s resting block followed with a fixation cross 
in the middle of the screen (DS:_DN:_PS:_DS:_).
Image Processing
The SPM 12 software (Statistical Parametric Mapping, http://
www.fil.ion.ucl.ac.uk/spm/) was used for the processing the 
functional data. The images were realigned, co-registered with the 
structural ones, normalized to Montreal Neurological Institute 
space, and smoothed with a 8 mm full-width-at-half-maximum 
Gaussian kernel. A general linear model was defined and the 
F-contrast on all three conditions was derived. The F-contrast 
map of each participant was used in the following analysis.
Multivariate Analysis
MLM is a method that is applied on the highly-dimensional 
data and creates a reduced set of features of the original data 
with minimal loss. The advantages of this method are threefold. 
First, unlike other dimension reduction methods such as 
principal component analysis (PCA), MLM takes into account 
information coming from the data (Y) and the information 
(contextual, experimental, behavioral, etc.) encoded in design 
matrix (X).
Second, MLM is specially adapted to fMRI data in particular 
taking into account temporal autocorrelation of the noise. Third, 
as MLM takes into account noise, it can be embedded into 
statistical framework for making inferences. We choose MLM 
because it is the most suited for fMRI data. The MLM analysis is 
implemented in the SPM toolbox Multivariate Methods for fMRI 
(https://github.com/LREN-CHUV/MLM).
We went through the following steps in our analysis: 
1) First, we performed an MLM analysis for each individual 
(Figure 1, Individual Level MLM). The individual MLM 
analyses identify for each participant the brain patterns that 
explain most of the changes in the fMRI activity and that 
are most correlated with the clinical conditions (PS, DS, 
and DN).
Our paradigm, as described earlier, was represented in a 
design matrix X which encoded three types of stimuli (PS, 
DS, and DN). Nuisance covariates included the six rigid body 
motion parameters were also added to the design matrix.
According to MLM algorithm, for each subject i 
(i=1..s) we calculate the principal components of matrix 
Z X X X Yi i i i i i= ( )−' / 'Σ 1 2 , where Xi is a design matrix [time by 
covariates (three conditions and nuisance covariates)], Yi is a 
data matrix (time by voxel), X Yi i
'  is their complex correlation 
normalized with X Xi i i
' /  Σ( )−1 2 , Σi  represents the temporal 
covariance matrix of the data. For each matrix Zi we search 
the decomposition Z U Vi i i i=   
'Λ , where Ui model parameters 
eigenvectors, Λi  diagonal matrix of eigenvalues, Vi spatial 
eigenvectors. The model parameters eigenvectors are referred 
as clinical loadings and the spatial eigenvectors are referred 
as eigenimages. To consider only three active conditions (PS, 
DS, and DN), the space of interest for MLM analysis was 
defined by an F-contrast encompassing these condition, as 
mentioned earlier. As a result, we obtained three eigenimages 
for each subject that are used at the next step.
2) Second, to summarize the information from the individual 
MLMs, we then performed a second MLM analysis (Figure 
1, Group Level MLM) using the brain patterns from the 
previous step while removing the confounding effects of age 
and gender.
Thus, at this step we build the matrix 
Z X X X YG G G G G G= ( )−' / 'Σ 1 2  where XG is the design matrix 
[subjects by covariates (diagnostic groups, age, gender)], and 
YG=[V1,V2,…,Vs] is a concatenation of eigenimages (number 
of active conditions by voxel) of each subject. We decompose 
matrix      
'Z U VG G G G= Λ . The VG identify the most consistent 
brain pattern across individuals in terms of variance 
explained, while to quantify individual differences we use the 
subject loadings UG (i.e. the contribution of each subject to 
the main brain pattern).
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3) In the last step we applied a linear discriminant analysis 
classifier (LDA in Statistics and Machine learning toolbox, 
version 11.0, Matlab R2016b) on each of the three subject 
loadings. The purpose of this final step is to test if the brain 
signatures can accurately discriminate the two clinical entities. 
Statistical significance of the final results, meaning the ability 
to discriminate diagnostic groups using unthresholded brain 
signatures was ensured by the use of linear discriminant 
analysis and k-fold cross-validation. We report the accuracy 
of classification with receiver operating characteristic 
(ROC) curves.
Figure 1 describes the schematic of our approach for 
discovering the brain signatures. To identify the brain 
signatures, we use multivariate method both at individual and 
group/population levels.
ReSUlTS
Demographic and Clinical Characteristics
The two patient groups did not differ significantly in their 
demographic and clinical characteristics (Table 1).
MlM Results
The individual MLMs showed a consistent profile across the 
different participants (see Figure 2, Clinical Loadings to the right 
side). In all the subjects, the first component that explained most 
of the variance corresponds to positive loading for the DS and 
DN and negative loadings for PS. The second component, shows 
a positive loading for DS and PS and negative loadings for DN, 
finally the last component shows a positive loading for PS and 
DN and a negative loading for DS.
FIgURe 1 | Procedure stages: 1) Individual MLM: MLM decomposed covariance matrix between the fMRI data and the design matrix which contained the clinical 
scale. As a result, we obtained three components (or clinical loadings) and three brain signatures (or eigenimages). 2) Group MLM: The individual eigenimages 
obtained from the previous step for each subject are aggregated in the group analysis, and MLM analysis is performed on the covariance matrix between 
eigenimages and the design matrix which contained the diagnostic label and confounding variables (gender and age). As a result we obtained group level brain 
signatures (or eigenimages) and the subject loadings that discriminate between the diagnostic groups. 3) To test the predictive ability of the brain signature we use 
linear discriminant analysis and the subject loadings to classify the individuals in two diagnostic groups and test the accuracy rates using k-fold cross-validation.
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Following the individual and group MLM, we identified the three 
brain patterns that summarized all the individual variabilities of the 
individual brain patterns (see Figure 2). The first brain signature 
shows positive pattern that covers visual parietal, motor cortices 
and it also expands to the frontal lobes. The second brain signature 
was mostly characterized by a positive pattern in the temporal 
and negative pattern in the frontal and parietal lobes. Finally, 
the third signature had mainly medial temporal and mid-frontal 
contributions for the positive and negative signature respectively.
Figure 3 (left) represents the accuracy of the linear 
discriminant analysis on subjects’ loadings for three signatures. 
The signatures were taken both for positive and negative patterns 
without thresholding. The accuracy was measured using k-fold 
cross validation with k = 2 and repeated 100 times to estimate 
the medians and 25th and 75th percentiles of its distribution. The 
median accuracy was respectively 0.67, 0.83, 0.90 for the first, 
second, and third signatures respectively. The performance of 
the classifier for each signature is measured with the ROC curves 
using schizophrenic group as reference (Figure 3, right).
DISCUSSION
In this current research, we have been able to separate the two 
investigated clinical entities—schizophrenia and depression by 
use of brain signatures derived from a task related fMRI where 
the paradigm comprised of answering to a self-assessment scale. 
This is a confirmation of the possibility to achieve bottom-up 
classification of mental disorders, by use of the brain signatures 
relevant to clinical evaluation tests.
However, there are several methodological issues to be discussed. 
On one hand, the small sample size might have influenced the 
results. On the other hand, the paradigm used was designed to 
discriminate between schizophrenia and depression by means of 
a contrast of the BOLD signal acquired during the depression and 
paranoia items processing but as we know both from clinical practice 
and psychiatric research these two domains may overlap (21). 
Symptoms of depression are often seen in schizophrenia and PCA 
of the PANSS items has revealed an anxio-depressive component 
highly correlated with other depression scales Hamilton depression 
rating scale (HAM-D), Calgary Depression Scale for Schizophrenia 
(CDSS) (16). Moreover, by means of PCA of ten frequently used 
negative symptom scales and structural brain imaging, Chuang et al. 
were able to find distinct correlation between the components and 
the white and gray matter volumes of different regions in a group of 
patients with schizophrenia and depression respectively (22).
Despite these limitations our study is adding to the growing 
body of evidence that multivariate approaches can be reliably used 
for distinguishing major psychiatric disorders by their respective 
brain signatures. For example, patterns derived from structural 
MRI have been used to discriminate between schizophrenia and 
healthy controls with high specificity and sensitivity ranging 
from 80% to 90%, and a bit less than 90% for schizophrenia 
versus bipolar disorder, as well as around 80% when compared to 
major depression (23–26).
Connectivity measures have also been used to distinguish 
between schizophrenia and healthy controls or depressed 
patients with an accuracy rate of 70% to 80% (27, 28). In a 
multisite study on fMRI (obtained under resting or different 
cognitive and emotional tasks), Orban et al. were able to 
achieve a discrimination rate of schizophrenia patients versus 
healthy controls as high as 84% (29). Thus, our accuracy rate 
of 67% to 90% is comparable to the results stated in most of 
the published literature to date. However, surprisingly the first 
two components that explain most of the variance did not 
necessarily led to the highest accuracy. This highlights again the 
limitation of psychiatric diagnostic entities. Put simply, there 
is a lot of variance due to biological processes although related 
to the disease that do not entirely correspond to the diagnostic 
groups. The first two brain signatures presents high contribution 
of the sensory cortices (motor or visuals), the third signature 
shows brain patterns with high loads in the temporal, parietal, 
and frontal regions. Unlike previous methods our two step 
hierarchical approach using semi unsupervised method allows to 
uncover these underlying biological processes and to identify the 
ones predictive of the diagnostic groups.
Moreover, what distinguishes our research from similar 
classification studies in the field is that our paradigm is based 
on the application of clinically relevant evaluation tools (in this 
case the PD-S) not just resting state or tasks that are irrelevant to 
the everyday patient assessment. In this way, our approach has 
the potential to practically bridge the gap between neuroscience 
and bedside care. We believe that the current research represents 
an advancement of the theoretical concept of the translational 
validation supporting it with further empirical results (25).
In contrast to our previous study where classical contrasting 
of the BOLD-signal elicited by the processing of the paranoia 
or depression items has failed to reveal statistically significant 
differences between the two clinical samples (despite the 
apparent differences), here by means of PCA and MLM we 
have achieved a meaningful distinction on the group level in a 
bottom-up fashion. This is in support of the further use of these 
TABle 1 | Demographic and clinical characteristics of the samples.
Schizophrenia patients (n = 16) Depressed patients (n = 14) Statistical significance
Age (mean ± SD) 36.4 ± 12.5 45.3 ± 12.5 0.064a
Sex (M/F) 10/6 5/9 0.143b
Education (secondary/higher) 11/5 8/6 0.452b
Age at onset (years) 28.5 ± 7.7 35.9 ± 11.2 0.099a
Illness duration (months) 93.8 ± 84.6 145.0 ± 86.0 0.200a
Episode duration (weeks) 8.6 ± 6.3 11.7 ± 9.4 0.419a
SD, standard deviation. a Independent samples t-test, bχ2 test.
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techniques as they might better reflect the complexity of both the 
neuroimaging data as such and the respective diagnostic classes.
CONClUSION
This paper is supposed to complement our previous publications 
(6–8) which used conventional approach for top-down cross-
validation of clinical self-evaluation diagnostic scale and fMRI, 
with rather limited results. Here, we demonstrate that by use of 
the items from the same clinical scale as fMRI stimuli and the 
means of machine learning it is possible to discover the brain 
signatures behind different psychiatric diagnostic classes and 
respective clinical measures.
This approach may potentially encourage in future 
re-validation of both psychiatric classifications and methods 
of assessment based on more robust neuro-biological evidence.
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FIgURe 2 | Brain signatures and subject loadings across all participants. Panels A, B, and C show the subject loadings for the first, second and third components, 
the corresponding signature and the clinical loadings. The subject loadings are shown as the solid blue line on the graph, the dotted line represents the projection 
of subject loadings in the design space (the units are arbitrary). The signatures represent the correlation between the subjects loadings and the value at each 
voxels. We project the strength of this correlation measure by a T-test on a 3D brain for illustration purposes, please note that the only valid test is the multivariate 
test that take into account all the voxels in the brain (see Kherif 2002 for details) and all the voxels with the appropriate weighting are taken into consideration when 
performing classification. The clinical loadings are the averaged clinical loadings of each subject calculated at the individual level MLM and weighted by the subject 
loading obtained at the group level MLM. (A) The highest peaks (T > 3.40, p < 0.001, uncorrected) for the positive pattern were located in the parietal cortex, 
precuneus, inferior occipital cortex, thalamus, interior cingulate gyrus, postcentral gyrus. There were no voxels significantly different from zero at the same threshold 
for negative pattern. (B) The highest peaks (T > 1.7, p < 0.05, uncorrected) for the positive pattern were located in the central operculum, superior temporal gyrus, 
and left hippocampus. The highest peaks (T > 1.7, p < 0.05) for the negative pattern were located in the superior frontal gyrus, middle frontal gyrus, angular gyrus. 
(C) The highest peaks (T > 1.7, p < 0.05, uncorrected) for the positive pattern were located in the lingual gyrus, precuneus, planum temporale, hippocampus, and 
insula. The highest peaks (T > 1.7, p < 0.05) for the negative pattern were located in the middle frontal gyrus, superior frontal gyrus, and angular gyrus.
FIgURe 3 | On the left: Accuracy of the classifier for three signatures for predicting the diagnostic labels. The accuracies were obtained by cross-validation repeated 
100 times to obtain the percentiles. The highest accuracy was obtained with the brain signature 3. On the right: Performance measurement of the classifiers for 
three signatures with receiver operating characteristic curve.
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